Hypertension, hemorrhagic stroke and smoking cessation

María Reverte1,2, Sergio Aparicio-Erroz3, Raquel López de la Fuente4

1 Instituto de Neurociencias de Castilla y León, Universidad de Salamanca, Spain
2 Departamento Fisiología y Farmacología, Facultad de Medicina, Universidad de Salamanca, Spain
3 Hospital Clínico Universitario de Salamanca, Universidad de Salamanca, Spain
4 Departamento de Medicina, Facultad de Medicina, Universidad de Salamanca, Spain

key words: stroke • smoking cessation • hypertension • cardiovascular risks • bupropion

SUMMARY

Background: Smoking cessation is considered as a good solution for stroke prevention. Unfortunately, first-line therapies to reduce cigarette smoking are not always useful. Some clinical effects of these drugs are able to produce cardiovascular adverse events.

Case report: We present the case of a woman with hypertension, well treated with bisoprolol, who has a nonfatal hemorrhagic stroke event due to an exacerbation of baseline hypertension. The addition of an atypical antidepressant for smoking cessation to her antihypertensive treatment would be the cause of this cerebrovascular accident.

Conclusions: Drug therapy is a logical approached. A rational therapeutic decision includes selecting patients and specific drugs. Perhaps, bupropion, an atypical antidepressant, may not be useful for smoking cessation if patients are hypertensives and well treated with specific drugs. This drug is unable to reduce cardiovascular risks in those patients.

BACKGROUND

Control of risk factors and enhancement of protective factors are the keystones to avoid hemorrhagic stroke [1]. Smoking cessation is important for the prevention of this illness [2]. The use of pharmacological agents to control tobacco addition is irrefutable [3,4]. Unfortunately, first-line therapies are not always safety [4,5]. Some of these drugs are able to induce cardiovascular adverse events. Here, we present a case of a hypertensive patient with a hemorrhagic stroke due to drug-drug interaction, by the addition of an atypical antidepressant for smoking cessation to her well control antihypertensive treatment.

CASE REPORT

A 44-year-old woman was referred to the hospital because of left frontal headache, nausea and vomiting. On admission, the patient was conscious and had a blood pressure of 200/100 mm Hg. The neurological examination revealed a mild motor aphasia, a left hemiparesis and a slight neck retraction. The patient was diagnosed 10 years ago of essential hypertension and treated with bisoprolol (10 mg per day). She had also been a smoker for 25 cigarettes per day, but she had discount smoking approximately 2 months ago. 10 days before she stopped smoking she began to be treated with bupropion (150 mg per day). The laboratory studies were all normal, except for a high plasma glucose levels (200 mg/dl). Computerized tomography, an established tool for the diagnosis of stroke [6], demonstrated different signs of acute haemorrhage stroke (Figure 1).

DISCUSSION

Per se smoking and hypertension are established risk factors for hemorrhagic stroke in men [2,7]. In both cases pharmacological agents could be used to favour smoking cessation [4] and reduce blood pressure levels [8]. However, the combination therapy using an antihypertensive drugs and antidepressants for to treat both diseases at the same time may not
be safer, as we shown in this case report, and not necessary could be related to a drug-drug interaction on CYP2D6 metabolism [9,10].

It is certainly that the rise in blood pressure was the potential mediator that caused the rupture of brain arteries and produced the hemorrhagic stroke in this young woman. In our case report the neurovisualization confirmed the brain damage. Nevertheless, the woman was previously well treated with bisoprolol, a selective β₁-adrenoceptor antagonist devoid of partial agonist activity that is often used for the treatment of hypertension [11]. Perhaps, the secondary addition of bupropion chronically to the beta-blocker could induce the hypertensive emergency.

Bupropion is an atypical antidepressant using for smoking cessation [5,12,13]. Experimental data have evidenced that this drug is a relatively weak inhibitor of norepinephrine and dopamine reuptake mechanisms. This drug has also an indirect role on serotonin (5-HT) neuronal elements [14]. Bupropion is able to increase plasma norepinephrine levels in rats [15], an important mechanism to develop hypertension and favor stroke [8]. Recently data in healthy male subjects demonstrate that the main mechanism of action of bupropion is to enhance synaptic availability of norepinephrine by increasing its release [16].

For several authors, hypertension is considered as a confounder factor between the possible connexion of the use of antidepressants and stroke [17]. In general, pharmaceutical products containing bupropion are not related to an increase risk for stroke, although several reports evidence an exacerbation in baseline hypertension [18,19]. We must to observe that in hypertension there is an increase in the density of sympathetic innervation in human and a faulty norepinephrine reuptake [20]. If we give bupropion chronically in combination with a selective β₁-adrenoceptor antagonist, like bisoprolol, we did not inhibit all the vascular effects of norepinephrine, a neurotransmitter of the sympathetic nervous system that stimulate different subtypes of α- and β-adrenoceptors. In the vast majority of vascular tissues (arteries and veins), α₁-adrenoceptors-mediated vasoconstriction and α₂-adrenoceptors-mediated the neural complex system regulating cardiovascular function [21]. A chronic increase in norepinephrine levels could evoke more increase in vascular tone and an overactivation of somatodendritic α₂-adrenoceptors. Desensitization of α₂-adrenoceptors, secondary to an increased exposure to the endogenous agonist ligand norepinephrine or prolonged occupation of the norepinephrine transporter [22,23], could produce more hypertension. It is not yet known whether all α-adrenoceptor subtypes are predominantly implicated. Perhaps, in this case report the association between bupropion and bisoprolol, a drug-drug interaction would be the cause of the exacerbation of the hypertension and the production of the hemorrhagic stroke that could never be mention.

CONCLUSIONS

Drug therapy is a logical approached. A rational therapeutic decision includes selecting patients and specific drugs. Perhaps, bupropion, an atypical antidepressant, may not be useful for smoking cessation if patients are hypertensives. This drug is unable to reduce cardiovascular risks in those treated-patients.

REFERENCES:

9. Guzey C, Norstrom A, Spigset O: Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit, 2002; 24: 436-437
22. Bawa T, Allenomi GF, Eikens DC, Stansifer KM: Desensitization of alpha(2A)-adrenoceptor signalling by modest levels of adrenaline is facilitated by beta(2)-adrenoceptor-dependent GRK3 up-regulation. Br J Pharmacol, 2003; 138: 921-931

Reverte M et al – Hypertension, hemorrhagic stroke and smoking…

Electronic PDF security powered by IndexCopernicus.com